GLP 1 News and Research

RSS

MIT engineers develop 'vibing belly' pill to control appetite and curb obesity

When you eat a large meal, your stomach sends signals to your brain that create a feeling of fullness, which helps you realize it's time to stop eating.

26 Dec 2023

Diabetes drug may help women avoid weight gain after quitting smoking

The diabetes drug dulaglutide (Trulicity) may significantly lower a woman's risk of substantial weight gain after she has given up smoking, finds a secondary analysis of clinical trial data, published in the open access journal BMJ Nutrition Prevention & Health.

19 Dec 2023

From diabetes drug to anti-inflammation powerhouse: The unexpected evolution of GLP-1

Research pioneer Dr. Daniel Drucker has much to be proud of, as the GLP-1-based diabetes drugs hailing from his early research are named 2023 breakthrough of the year by the Science Magazine.

18 Dec 2023

Science’s Breakthrough of the Year: GLP-1 agonists can blunt obesity-associated health problems

Science has named the development of glucagon like peptide-1 (GLP-1) agonists and this year's discovery that these drugs can blunt obesity-associated health problems as its 2023 Breakthrough of The Year.

15 Dec 2023

How safe are GLP-1R agonists in early pregnancy?

JAMA Internal Medicine study examines the safety of GLP-1 receptor agonists and other second-line antidiabetic medications during early pregnancy, finding no significant increase in congenital anomalies compared to insulin use.

14 Dec 2023

Poll: Vast majority of older adults think health insurers should cover obesity medications

The vast majority of older adults – 83% -- think health insurers should cover medications that can help people with obesity manage their weight, a new poll of people age 50 to 80 finds.

13 Dec 2023

Tirzepatide shows success in maintaining weight loss in obese adults

Study finds that the anti-obesity medication tirzepatide effectively maintains weight loss in obese adults, offering a promising approach to managing obesity and related health complications.

12 Dec 2023

Adherence to second-line drugs for Type 2 diabetes can be hit or miss, study reports

Most patients with Type 2 diabetes will end up needing to add a second-line medication after metformin -; the go-to primary drug for glucose management -; to control their blood sugar levels.

12 Dec 2023

Tirzepatide maintains weight loss and improves cardiometabolic health in SURMOUNT-4 trial

The current class of anti-obesity drugs is proving remarkably effective at removing excess pounds. However, a phase 3 randomized clinical trial led by researchers at Weill Cornell Medicine and NewYork-Presbyterian found that people who stopped taking the medication regained much of that weight within a year.

11 Dec 2023

Second-line diabetes drugs safe for babies? New study offers reassurance

Infants born to women with pre-gestational type 2 diabetes who take second-line non-insulin antidiabetic medications (ADMs) during pregnancy are at no higher risk of major congenital malformations (MCMs) than infants born to those who take insulin, according to a new study led by Harvard T.H. Chan School of Public Health.

11 Dec 2023

Study explores the intricate gut-brain-liver connection and its impact on health

Study reviews the gut-brain-liver axis, revealing the complex interplay between these organs in health and disease and the implications for therapeutic interventions, focusing on how gut microbiota affects liver and brain health.

10 Dec 2023

A class of diabetes medications may reduce the risk of colorectal cancer

A groundbreaking study by researchers at Case Western Reserve University suggests a class of medications used to treat type 2 diabetes may also reduce the risk of colorectal cancer (CRC).

7 Dec 2023

Groundbreaking studies indicate Semaglutide and Tirzepatide may reduce alcohol consumption in individuals with obesity

The impact of semaglutide and tirzepatide and glucagon-like peptide-1 receptor agonist medications on alcohol consumption.

1 Dec 2023

The role of the brainstem in appetite suppression

The role of the brainstem in appetite suppression.

28 Nov 2023

New insights into the brain's control of eating speed

When you eagerly dig into a long-awaited dinner, signals from your stomach to your brain keep you from eating so much you'll regret it – or so it's been thought.

22 Nov 2023

Single injection of novel hydrogel could replace weekly diabetes injections

Materials engineers at Stanford University have developed a novel hydrogel drug delivery system that transforms daily or weekly injections of diabetes and weight control drugs like Ozempic, Mounjaro, Trulicity, Victoza, and others to just once every four months.

22 Nov 2023

SELECT trial: Semaglutide reduces cardiovascular events by 20% in overweight or obese patients without diabetes

Findings from a multi-center, international clinical trial reported by a Cleveland Clinic physician show that semaglutide reduced cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease who do not have diabetes.

13 Nov 2023

Study highlights safety concerns of SGLT2i in patients with diabetes and cancer

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have heart- and kidney-related benefits for patients with and without diabetes that go beyond their initial indication for lowering blood sugar levels.

2 Nov 2023

Citrus compounds show zesty promise in type 2 diabetes management

Citrus compounds show promise in type 2 diabetes management, reducing blood glucose and mitigating metabolic complications without a clear threshold in humans for bioflavonoid efficacy.